Bloomberg

Capital Group's Noriko Chen says this market disruption looks "a little bit more temporary" as it's mainly about short-term energy supplies rather than oil and gas production. She tells Bloomberg Television that while inflation will run higher, it's not expected to have a big impact on the global economy.

Bob O'Donnell, President and Chief Analyst at Technalysis Research, says Apple will maintain its AI focus during the leadership change. He notes that incoming CEO John Ternus is well-positioned to build on his extensive hardware experience.

In a matter of months, Google's AI chips have become one of the hottest commodities in the tech sector. Leading artificial intelligence developers, including some of the firm's biggest rivals, are stocking up on them. Now, the Alphabet Inc.-owned company aims to build on its momentum with the likely introduction of new chips dedicated to inference, or running AI models after they've been trained. With this push, Google is poised to further challenge market leader Nvidia Corp. in a fast-growing category for semiconductors that's fueled by surging adoption of AI software. Bloomberg News AI Infrastructure Reporter Dina Bass joins Bloomberg Businessweek Daily to discuss. She speaks with Carol Massar and Tim Stenovec.

"Apple is in good shape," Gil Luria, D.A. Davidson head of technology research, says while reacting to Apple naming John Ternus as the iPhone maker's next leader, with Tim Cook shifting to the role of executive chairman. He speaks on "Bloomberg The Close."

Shares of companies involved in psychedelic-tied therapies surged Monday after President Donald Trump signed an executive order to expedite research and access. US-traded shares of Compass Pathways spiked as much as 53% while AtaiBeckley surged by 37%. GH Research jumped 34% and Definium Therapeutics rallied 16%. The AdvisorShares Psychedelics ETF (PSIL) also climbed as much as 20% touching its highest intraday level since July 2023. The new order directs the US Food and Drug Administration to issue expedited review vouchers to psychedelics with a so-called breakthrough designation, shortening the review time to one to two months from six to ten months. AtaiBeckley, Definium and Compass Pathways all have therapies with breakthrough status. Compass Pathways CEO Kabir Nath joins Bloomberg Businessweek Daily to discuss. He speaks with Carol Massar and Tim Stenovec.

"I couldn't be happier about it," Gerber Kawasaki Wealth and Investment Management co-founder and CEO Ross Gerber says while reacting to Apple naming John Ternus as the iPhone maker's next leader, with Tim Cook shifting to the role of executive chairman. He speaks on "Bloomberg The Close."

Apple Inc. named hardware chief John Ternus as the iPhone maker's next leader, with Chief Executive Officer Tim Cook shifting to the role of executive chairman.  Ternus will become CEO on Sept. 1, the company said in a statement Monday. The Apple veteran was head of hardware engineering since 2021 and has spent 25 years focused on product development at the iPhone maker. Bloomberg News previously reported that Ternus was Cook's heir apparent.

FDA Commissioner Dr. Marty Makary discusses President Trump's Executive Order aimed at faster research and access to psychedelics, citing promising research and calling this an 'historic moment.' He talks with Romaine Bostick and Katie Greifeld on "The Close."

BMO Chief FX Strategist Mark McCormick says the right trade is to be long dollar for now. He speaks on "Bloomberg The Close."

Michael Baron, co-president and portfolio manager at Baron Capital, joins Katie Greifeld, Scarlet Fu, and Eric Balchunas on "Bloomberg ETF IQ." They discuss Baron Capital's entrance into the ETF space and the firm's investment in SpaceX.